Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
Aquestive and Eton announced an exclusive U.S. licensing and supply agreement for LIBERVANT (diazepam) buccal film, transferring U.S. commercialization rights to Eton. Eton anticipates commercial availability in April 2027, subject to final FDA approval; full approval in patients 12+ is expected after VALTOCO's orphan exclusivity expires January 10, 2027, and a label-expansion NDA (ages 6-11) has a PDUFA date of March 29, 2027.
Key figures
- Drug Name
- LIBERVANT (diazepam) buccal film
- Patent protection
- into 2038
- Pdufa target date
- March 29, 2027 (age 6-11 label expansion NDA)
- Anticipated launch
- April 2027, subject to final FDA approval
- Us market opportunity
- $450 million annually
- Orphan exclusivity expiration valtoco
- January 10, 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.